[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530025":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":39,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Amine Benmassaoud, MD","CONTACT","514-934-1934","amine.benmassaoud@mcgill.ca",{"name":15,"role":11,"phone":12,"phoneExt":16,"email":17},"Olivia Geraci, BSc","34868","olivia.geraci@muhc.mcgill.ca",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"McGill University Health Centre","RECRUITING","Montreal","Quebec","H3G1A4","Canada","CA",{"type":28,"coordinates":29},"Point",[30,31],-73.58781,45.50884,{"lat":31,"lon":30},[34,36],{"name":10,"role":11,"phone":35,"phoneExt":7,"email":13},"5149341934",{"name":37,"role":11,"phone":35,"phoneExt":7,"email":38},"Myriam Martel, MSc","myriam.martel@muhc.mcgill.ca",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Amine Benmassaoud","Division of Gastroenterology and Hepatology Assistant Professor of Medicine","100530025","lsm-and-ssm-for-the-diagnosis-of-csph-a-prospective-cohort-study-100530025",false,"NCT06181409","LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study","Diagnosing and Monitoring Portal Hypertension Non-invasively Using Spleen Stiffness Measurement in Patients With Advanced Chronic Liver Disease: a Prospective Cohort Study","Inclusion Criteria:\n\n* Age above 18years old\n* Advanced chronic liver disease (defined as LSM ≥ 10kPa)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Transjugular intrahepatic portosystemic shunt\n* previous liver transplantation\n* Abnormality of the porto-mesenteric system (portal vein thrombosis, splenic vein thrombosis, splenectomy, portal cavernomatous transformation, porto-caval shunts)\n* Hematological malignancy","ALL","18 Years",{"count":53,"type":54},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess non-invasive tools' efficacy in predicting portal hypertension-related complications in individuals with advanced chronic liver disease. The main question it aims to answer are:\n\n\\- what are the cut-off values for non-invasive tests (NITs) (including LSM, SSM) that predict the presence and occurrence of hepatic decompensation in individuals with advanced chronic liver disease?\n\nParticipants will undergo regular study visits involving non-invasive tests (LSM, SSM) and assessments to monitor hepatic decompensation over the study period.",[58],"Advanced Chronic Liver Disease","2026-03-10",{"date":61,"type":62},"2026-03-12","ACTUAL",{"date":64,"type":62},"2024-01-10",{"date":66,"type":54},"2028-12",{"name":5,"class":6},1]